Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
HCAT Stock Forecast 2025-2026
$3.89
Current Price
$270.75M
Market Cap
Buy 8
Hold 5
Sell 0
Wall St Analyst Ratings
Distance to HCAT Price Targets
+157.1%
To High Target of $10.00
+86.4%
To Median Target of $7.25
+28.5%
To Low Target of $5.00
HCAT Price Momentum
-4.2%
1 Week Change
+2.4%
1 Month Change
-39.9%
1 Year Change
-45.0%
Year-to-Date Change
-57.9%
From 52W High of $9.24
+11.5%
From 52W Low of $3.49
📊 TOP ANALYST CALLS
Did HCAT Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Health Catalyst is one of their latest high-conviction picks.
Latest HCAT Stock Price Targets & Analyst Predictions
Based on our analysis of 20 Wall Street analysts, HCAT has a bullish consensus with a median price target of $7.25 (ranging from $5.00 to $10.00). The overall analyst rating is Strong Buy (8.2/10). Currently trading at $3.89, the median forecast implies a 86.4% upside. This outlook is supported by 8 Buy, 5 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Stan Berenshteyn at Wells Fargo, projecting a 157.1% upside. Conversely, the most conservative target is provided by Scott Schoenhaus at Keybanc, suggesting a 28.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
HCAT Analyst Ratings
8
Buy
5
Hold
0
Sell
HCAT Price Target Range
Low
$5.00
Average
$7.25
High
$10.00
Current: $3.89
Latest HCAT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for HCAT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jul 9, 2025 | Evercore ISI Group | Elizabeth Anderson | In-Line | Maintains | $4.00 |
| May 8, 2025 | Stifel | David Grossman | Hold | Maintains | $5.50 |
| May 8, 2025 | Canaccord Genuity | Richard Close | Buy | Maintains | $9.00 |
| Apr 25, 2025 | Citigroup | Daniel Grosslight | Buy | Maintains | $6.50 |
| Apr 16, 2025 | Keybanc | Scott Schoenhaus | Overweight | Maintains | $5.00 |
| Apr 9, 2025 | Evercore ISI Group | Elizabeth Anderson | In-Line | Downgrade | $4.00 |
| Mar 6, 2025 | Stephens & Co. | Jeff Garro | Equal-Weight | Maintains | $5.00 |
| Feb 27, 2025 | Stifel | David Grossman | Hold | Maintains | $5.00 |
| Feb 27, 2025 | Stephens & Co. | Jeff Garro | Equal-Weight | Reiterates | $7.00 |
| Feb 27, 2025 | RBC Capital | Sean Dodge | Sector Perform | Maintains | $6.00 |
| Feb 11, 2025 | Piper Sandler | Jessica Tassan | Overweight | Maintains | $8.00 |
| Jan 21, 2025 | Wells Fargo | Stan Berenshteyn | Overweight | Maintains | $10.00 |
| Jan 21, 2025 | Canaccord Genuity | Richard Close | Buy | Maintains | $10.00 |
| Jan 15, 2025 | RBC Capital | Sean Dodge | Sector Perform | Maintains | $7.00 |
| Jan 10, 2025 | Citigroup | Daniel Grosslight | Buy | Maintains | $10.00 |
| Jan 8, 2025 | Keybanc | Scott Schoenhaus | Overweight | Upgrade | $9.00 |
| Nov 26, 2024 | Piper Sandler | Jessica Tassan | Overweight | Reiterates | $12.00 |
| Nov 14, 2024 | Stephens & Co. | Jeff Garro | Equal-Weight | Maintains | $9.00 |
| Nov 13, 2024 | Citigroup | Daniel Grosslight | Buy | Maintains | $10.50 |
| Nov 7, 2024 | RBC Capital | Sean Dodge | Sector Perform | Maintains | $9.00 |
Health Catalyst Inc. (HCAT) Competitors
The following stocks are similar to Health Catalyst based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
HCAT
Health Catalyst
mkt cap
270.75M
Health Catalyst Inc. (HCAT) Financial Data
Health Catalyst Inc. has a market capitalization of $270.75M with a P/E ratio of -3.4x. The company generates $311.27M in trailing twelve-month revenue with a -23.3% profit margin.
Revenue growth is +6.3% quarter-over-quarter, while maintaining an operating margin of -17.1% and return on equity of -19.8%.
Valuation Metrics
Market Cap
$270.75M
Enterprise Value
$322.79M
P/E Ratio
-3.4x
PEG Ratio
9.3x
Price/Sales
0.9x
Growth & Margins
Revenue Growth (YoY)
+6.3%
Gross Margin
+45.6%
Operating Margin
-17.1%
Net Margin
-23.3%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+126.3%
Current Ratio
1.2x
Debt/Equity
106.8x
ROE
-19.8%
ROA
-4.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Health Catalyst Inc. (HCAT) Business Model
About Health Catalyst Inc.
What They Do
Provides data and analytics solutions for healthcare.
Business Model
The company operates by offering a comprehensive software platform called Data Operating System (DOS), which aggregates and analyzes healthcare data. Health Catalyst generates revenue by providing solutions that enhance decision-making processes for healthcare providers, helping them reduce costs, improve patient care, and increase operational efficiency.
Additional Information
Health Catalyst is recognized for its significant role in the digital transformation of healthcare, focusing on innovative big data utilization. As healthcare organizations shift towards technology adoption, the company is well-positioned to support these institutions in achieving improved clinical and financial outcomes.
Company Information
Sector
Healthcare
Industry
Health Information Services
Employees
1,500
CEO
Mr. Daniel D. Burton
Country
United States
IPO Year
2019
Website
www.healthcatalyst.comHealth Catalyst Inc. (HCAT) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
VEEV Rises 29% in 3 Months: Should You Buy the Stock Now or Wait?
Veeva Systems gains momentum as strong earnings, Vault CRM growth, and new AI tools reinforce its life sciences edge.
Jul 08, 2025
By Harshit Gupta
Analyst Blog
Can OptimizeRx Maintain Profit Growth Amid Evolving Pharma Spend?
OPRX raised guidance after record Q1 EBITDA, but pharma budget shifts and margin mix pose new challenges ahead.
Jul 04, 2025
By Indrajit Bandyopadhyay
Analyst Blog
Latest News
Quick Summary
Health Catalyst (Nasdaq: HCAT) has launched 10 AI-integrated data toolkits on Databricks Marketplace, aimed at addressing key healthcare challenges and offering free resources for improvement.
Why It Matters
Health Catalyst's launch of AI-integrated toolkits on Databricks Marketplace enhances its service offering, potentially boosting revenue and market share in the growing healthcare analytics sector.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Health Catalyst (HCAT) has been upgraded to Zacks Rank #2 (Buy), indicating improved earnings prospects, which could lead to a potential increase in the stock price.
Why It Matters
Health Catalyst's upgrade to a Zacks Rank #2 signals improved earnings outlook, likely driving investor confidence and potentially boosting the stock price.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Health Catalyst is rated a buy due to strong momentum and its Ignite platform, which boosts growth and margins. Recent financials indicate accelerating revenue and client additions, supporting FY25 guidance.
Why It Matters
Health Catalyst's strong turnaround and accelerating revenue growth, driven by the Ignite platform, signal potential for higher margins and significant upsell opportunities, enhancing investment appeal.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Health Catalyst, Inc. (Nasdaq: HCAT) announced CFO Jason Alger and VP of Investor Relations Jack Knight will attend investor conferences on June 3 and June 10, 2025, in Boston and Miami, respectively.
Why It Matters
Health Catalyst's participation in key investor conferences signals engagement with the investment community, potentially influencing stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Health Catalyst, Inc. (NASDAQ: HCAT) will hold its Q1 2025 earnings conference call on May 7, 2025, at 5:00 PM ET, featuring key executives and financial analysts.
Why It Matters
Health Catalyst’s Q1 2025 earnings call will provide insights into financial performance and future outlook, influencing stock valuation and investment decisions.
Source: Seeking Alpha
Market Sentiment:
Neutral
Health Catalyst Reports First Quarter 2025 Results
2 months ago
Quick Summary
Health Catalyst (Nasdaq: HCAT) reported Q1 2025 revenue of $79.4 million and Adjusted EBITDA of $6.3 million, surpassing quarterly guidance.
Why It Matters
Health Catalyst's Q1 2025 results, exceeding revenue and EBITDA guidance, signal strong operational performance and potential for continued growth, positively influencing investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About HCAT Stock
What is Health Catalyst Inc.'s (HCAT) stock forecast for 2026?
Based on our analysis of 20 Wall Street analysts, Health Catalyst Inc. (HCAT) has a median price target of $7.25. The highest price target is $10.00 and the lowest is $5.00.
Is HCAT stock a good investment in 2026?
According to current analyst ratings, HCAT has 8 Buy ratings, 5 Hold ratings, and 0 Sell ratings. The stock is currently trading at $3.89. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for HCAT stock?
Wall Street analysts predict HCAT stock could reach $7.25 in the next 12 months. This represents a 86.4% increase from the current price of $3.89. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Health Catalyst Inc.'s business model?
The company operates by offering a comprehensive software platform called Data Operating System (DOS), which aggregates and analyzes healthcare data. Health Catalyst generates revenue by providing solutions that enhance decision-making processes for healthcare providers, helping them reduce costs, improve patient care, and increase operational efficiency.
What is the highest forecasted price for HCAT Health Catalyst Inc.?
The highest price target for HCAT is $10.00 from Stan Berenshteyn at Wells Fargo, which represents a 157.1% increase from the current price of $3.89.
What is the lowest forecasted price for HCAT Health Catalyst Inc.?
The lowest price target for HCAT is $5.00 from Scott Schoenhaus at Keybanc, which represents a 28.5% increase from the current price of $3.89.
What is the overall HCAT consensus from analysts for Health Catalyst Inc.?
The overall analyst consensus for HCAT is bullish. Out of 20 Wall Street analysts, 8 rate it as Buy, 5 as Hold, and 0 as Sell, with a median price target of $7.25.
How accurate are HCAT stock price projections?
Stock price projections, including those for Health Catalyst Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 13, 2025 3:07 PM UTC